nach oben

PharmacoEconomics

Erschienen in:

01.12.2001 | Review Article

Accounting for Noncompliance in Pharmacoeconomic Evaluations

verfasst von: Dr Dyfrig A. Hughes, Adrian Bagust, Alan Haycox, Tom Walley

Erschienen in: PharmacoEconomics | Ausgabe 12/2001

Einloggen, um Zugang zu erhalten

Abstract

Noncompliance with prescribed drug regimens is a widespread phenomenon which results in decreased efficacy and is often associated with increased medical expenditures. Despite this, economic evaluations based on decision-analytic models rarely incorporate noncompliance to allow for the differences in compliance observed between controlled clinical trials and routine clinical practice.

This review examines the issues relating to the measurement of noncompliance, and the clinical and economic consequences of noncompliant drug taking behaviour. In order to fully appreciate the clinical (and therefore the economic) consequences of noncompliance, a detailed understanding of the type of noncompliance, the pharmacokinetic and pharmacodynamic properties of the drug and the pathophysiological processes of the diseases being treated is required. These are described in detail, and a classification of drug-disease combinations according to the potential economic impact of the varying forms of noncompliance is set out.

Issues are raised to highlight the need for improved modelling of the impact of noncompliance, and to this end, recommendations are made for future analyses. The main points are that compliance should be defined clearly, distinguishing between the various forms of noncompliance, that the assumptions relating to the health status of noncompliers should be explicit and robust, and that sensitivity analysis should be applied appropriately to ascertain the impact of noncompliance on the cost-effectiveness of drug therapies.

Métry J-M, Meyer UA, editors. Drug regimen compliance: issues in clinical trials and patient management. Chichester: John Wiley, 1999

Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using ‘real world’ randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995; 48: 363–73PubMedCrossRef

Fayers PM, Hand DJ. Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet 1997; 350: 1025–7PubMedCrossRef

Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160: 41–6PubMed

Andrade SE, Saperia GM, Berger ML, et al. Effectiveness of antihyperlipidemic drug management in clinical practice. Clin Ther 1999; 21: 1973–87PubMedCrossRef

Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs — do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125–31PubMedCrossRef

Revicki DA, Frank L. Pharmacoeconomic evaluations in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15: 423–34PubMedCrossRef

Boudes P. Drug compliance in therapeutic trials: a review. Cont Clin Trials 1998; 19: 257–68CrossRef

Urquhart J, De Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med 1998; 17: 251–67PubMedCrossRef

10.

Beardon PHG, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medications in primary care. BMJ 1993; 307: 846–8PubMedCrossRef

11.

Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Info J 1988; 22: 363–78

12.

Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345–56PubMedCrossRef

13.

Claxton AJ, Cramer JA, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310PubMedCrossRef

14.

Jones JK, Gorkin L, Lian JK, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293–5PubMedCrossRef

15.

Oster G, Borok GM, Menzin J, et al. Cholesterol-reduction intervention study (CRIS): a randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med 1996; 156: 731–9PubMedCrossRef

16.

Simmons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164: 208–11

17.

Avorn J, Monette J, Lacour A, et al. Persistence of use of lipidlowering medications: a cross-national study. JAMA 1998; 279: 1458–62PubMedCrossRef

18.

Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manage Care 1999, 5: 437–44

19.

Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310: 1433–8PubMedCrossRef

20.

Paes AHP, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci 1998; 20: 73–7PubMedCrossRef

21.

Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol 1997; 37: 451–75PubMedCrossRef

22.

Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989; 46: 169–76PubMedCrossRef

23.

Pullar T, Kumar S, Tundall H, et al. Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163–8PubMedCrossRef

24.

Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J 1992; 68 Suppl. 3: S49–59

25.

Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 1999; 52: 1138–45PubMedCrossRef

26.

Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder, the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998; 17: 599–611PubMedCrossRef

27.

Shiell A, Brown S, Farrell GC. Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust 1999; 171: 189–93PubMed

28.

Psaty BM, Koepsell TD, Wagner ED, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of β-blockers. JAMA 1990; 263: 1653–7PubMedCrossRef

29.

Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996; 276: 1955–6PubMedCrossRef

30.

Urquhart J. Erratic compliance with prescribed drug regimens: target for drug delivery systems. Clin Pharmacol Ther 2000; 67: 331–4PubMedCrossRef

31.

Young A, Haddad P. Discontinuation symptoms and psychotropic drugs [letter]. Lancet 2000; 355: 1184PubMedCrossRef

32.

Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601–15PubMedCrossRef

33.

Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999; 15: 217–28PubMedCrossRef

34.

Lafata JE, Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15: 31–7PubMedCrossRef

35.

Drummond MF, editor. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

36.

Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217–27PubMedCrossRef

37.

Rosner AJ, Grima DT, Torrance GW, et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998; 14: 559–73PubMedCrossRef

38.

Hughes D, Manns B. Patient compliance with drug therapy for diabetic nephropathy [letter]. CMAJ 2000; 162: 1553PubMed

39.

Harter JG, Peck CC. Chronobiology: suggestions for integrating it into drug development. Ann NY Acad Sci 1991; 618: 563–71PubMedCrossRef

40.

Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacol 1992; 22: 238–46CrossRef

41.

Wang W, Husam F, Chow S-C. The impact of patient compliance on drug concentration profile in multiple doses. Stat Med 1996; 15: 659–69PubMedCrossRef

42.

Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998; 17: 2313–33PubMedCrossRef

43.

Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997; 35: 401–13PubMed

44.

Gieschke R, Reigner BG, Steimer J-L. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997; 35: 469–74PubMed

45.

Holford NH, Kimko HC, Monteleone JP, et al. Clinical trial simulations. Ann Rev Pharmacol Toxicol 2000; 40: 209–34CrossRef

46.

Hughes DA, Bagust A, Haycox A, et al. The influence of noncompliance on the effectiveness and cost-effectiveness of drug therapies [abstract]. Value Health 2000; 3: 373CrossRef

47.

Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc R Soc Lond B 2000; 267: 835–43CrossRef

Titel: Accounting for Noncompliance in Pharmacoeconomic Evaluations
verfasst von: Dr Dyfrig A. Hughes
Adrian Bagust
Alan Haycox
Tom Walley
Publikationsdatum: 01.12.2001
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 12/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200119120-00001

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Accounting for Noncompliance in Pharmacoeconomic Evaluations

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2001

Direct Costs of Schizophrenia in Italian Community Psychiatric Services

Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS

Paclitaxel

Economic Evaluation of Collagenase-Containing Ointment and Hydrocolloid Dressing in the Treatment of Pressure Ulcers